U.S. Water Utilities Stock News

Wondering whether Taiwan Semiconductor Manufacturing stock still offers value after its strong run, or if you might be arriving late to the story? The share price last closed at US$414.15, with returns of 4.6% over 7 days, 19.9% over 30 days, 29.6% year to date, 138.6% over 1 year, 413.9% over 3 years and 306.3% over 5 years. Recent headlines have focused on Taiwan Semiconductor Manufacturing's central role in global chip supply and its position in advanced manufacturing capacity. This...

If you are wondering whether Grindr stock is priced fairly or if the current level still leaves room for value, you need to look past headlines and into the numbers that shape valuation. Over the last month the share price has moved to US$13.81, with returns of 3.3% over 7 days, 12.4% over 30 days and 3.8% year to date, set against a 43.5% loss over the past year and a 124.2% gain over three years. Recent coverage has focused on Grindr as a listed platform business and how investors are...

Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR). The vote clears a key milestone for the acquisition and allows the deal process to move toward closing. The transaction is expected to expand Danaher's presence in diagnostics and medical technology once remaining conditions are met. For investors watching NYSE:DHR, this approval matters because it comes at a time when diagnostics, patient monitoring and broader medical technology are central to hospital and...

If you are trying to figure out whether Apellis Pharmaceuticals is attractively priced today, it helps to start with how the current market value lines up against different ways of estimating fair value. The stock last closed at US$41.01, with returns of 0.1% over 7 days, 0.8% over 30 days, 58.6% year to date and 130.3% over the past year, alongside 3 year and 5 year returns of 53.7% decline and 10.1% decline respectively. This gives a mixed picture for anyone thinking about entry or exit...

Vistra (VST) has wrapped up FY 2025 with fourth quarter revenue of US$4.6b, Basic EPS of US$0.55 and net income of US$185m, rounding out a trailing twelve month picture that totals US$17.7b in revenue, Basic EPS of US$2.22 and net income of US$752m. Over recent quarters, reported revenue has moved from US$4.0b in Q4 2024 to US$4.6b in Q4 2025, while quarterly Basic EPS has ranged from US$1.16 in Q4 2024 to US$0.55 most recently, setting up a results season where investors are weighing...

Earlier this week, enGene Therapeutics reported interim Phase 2 LEGEND trial results for its bladder cancer gene therapy detalimogene voraplasmid, revealing a 54% complete response rate but weaker 12‑month durability than previously expected, alongside generally manageable side effects and low disease progression. The mixed efficacy profile has triggered analyst downgrades and shareholder-rights investigations, highlighting how a single data update can rapidly reshape perceptions of a...

If you are wondering whether Planet Labs PBC at around US$35.24 is priced attractively or already baking in big expectations, it helps to step back and look at how the stock has been behaving and what that might imply about value. The share price is around US$35.24, with a 4.7% decline over the last week, roughly flat at 0.2% over the past month, a 72.7% gain year to date, and a very large rise over the past year that is close to 9x, as well as very strong multi year returns. These moves...

NiSource (NYSE:NI) announced new and expanded partnerships with Amazon and Alphabet that are expected to support $1.4 billion in customer savings over 15 years. Alongside these partnerships, the company updated its long term adjusted EPS growth outlook to a range of 9% to 10% through 2033. For investors watching utilities, NiSource stands out with a current share price of $47.02 and a 5 year return of 115.2%. The stock has also returned 21.9% over the past year and 83.7% over 3 years,...

Geopolitical tensions and higher oil prices are pushing up ocean freight costs for Columbia Sportswear, raising questions about future gross margins. Renewed U.S. Iran frictions are contributing to more expensive international shipping, which could affect sourcing and distribution for Columbia's global business. These supply chain pressures come as investors focus on how apparel companies handle external cost shocks alongside consumer demand trends. Columbia Sportswear (NasdaqGS:COLM) is...

In the first quarter of 2026, Medical Properties Trust reported revenue of US$252.07 million and net income of US$32.83 million, reversing a prior-year net loss and lifting earnings per share from a loss of US$0.20 to a profit of US$0.05. This shift from loss to profit, alongside higher sales versus a year earlier, suggests management’s efforts to stabilize operations and rental income are beginning to show up in the company’s financial results. With Medical Properties Trust returning to...

This article examines whether Primo Brands, trading at around US$22.24, currently represents value or risk by exploring what the share price might be implying. The stock has returned 9.1% over the last 7 days, 21.3% over the last 30 days and 37.4% year to date, while the 1 year return reflects a 29.8% decline and the 3 and 5 year returns are 69.8% and 48.4% respectively. Recent market interest in Primo Brands appears tied to broader investor attention on beverage companies listed in the US...

Pitney Bowes (NYSE:PBI) received Impact Level 4 (IL4) Provisional Authorization for its SendPro 360 cloud platform. The IL4 approval permits use of SendPro 360 by the U.S. Department of Defense and authorized contractors. This accreditation expands access to secure federal technology workloads and supports the company’s government-focused offerings. Pitney Bowes, known for mailing, shipping, and related software, now has SendPro 360 cleared for higher security federal use through the IL4...

Why Disc Medicine’s latest trial milestones matter for investors Disc Medicine (IRON) has moved its pipeline forward by completing enrollment in the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, while also preparing new data readouts across other hematology programs. See our latest analysis for Disc Medicine. The latest trial milestones arrive after a mixed stretch in the market, with the share price at US$67.53 showing a 1-year total shareholder return of...

Guardant Health (GH) has just posted its FY 2025 numbers with Q4 revenue of US$281.3 million, a basic EPS loss of US$1.00 and net income loss of US$128.5 million, set against a trailing twelve month revenue base of US$982.0 million and a TTM EPS loss of US$3.32. Over recent quarters the company has seen revenue move from US$201.8 million in Q4 FY 2024 to US$281.3 million in Q4 FY 2025. Quarterly basic EPS losses have ranged between US$0.74 and US$1.00, and TTM net income losses have remained...

Encore Capital Group (NasdaqGS:ECPG) is asking shareholders to approve an amendment to its corporate charter. The change would exculpate company officers from personal liability for monetary damages tied to breaches of the duty of care. The proposal is scheduled for a vote at the upcoming annual shareholder meeting. Encore Capital Group operates in the consumer debt buying and collections space, where regulatory scrutiny, legal risk and reputational considerations tend to be front and...

Hartford Insurance Group (NYSE:HIG) released its latest "Future of Benefits Study," examining how U.S. workers are choosing benefits as inflation pressures household budgets. The research highlights growing use of AI tools by employees, especially younger generations, to compare and select benefits options. The findings shed light on changing expectations of workplace benefits and potential shifts in how employers structure their offerings. For a company like Hartford, which has a broad...

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations. The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk. Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline...

Wondering whether Privia Health Group at around US$23.99 is offering fair value or a potential opportunity? This article breaks down what the current price may be telling you. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 7.2% gain over the last 30 days, and year to date returns of 2.3% after a 4.3% loss over the past year. Those mixed returns come against a backdrop of ongoing interest in healthcare services companies focused on physician enablement and...

Motorola Solutions (MSI) closed out FY 2025 with fourth quarter revenue of US$3.4 billion and basic EPS of US$3.90, supported by net income of US$649 million. Trailing 12 month figures show revenue of US$11.7 billion and basic EPS of US$12.93. Over the past year, revenue has moved from US$10.8 billion to US$11.7 billion and basic EPS has gone from US$9.45 to US$12.93, alongside trailing 12 month net income rising from US$1.6 billion to US$2.2 billion. This sets the backdrop for a profit story...

If you are wondering whether IonQ's current share price lines up with its fundamentals, this article walks through the key signals investors often rely on when thinking about value. The stock last closed at US$47.68, with returns of 5.7% over 7 days, 67.4% over 30 days, 1.9% year to date and 49.7% over 1 year. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage has focused on IonQ as a pure play in quantum computing, with attention on...

PG&E stock after recent performance shifts PG&E (PCG) has seen recent share price pressure, with the stock showing a 0.1% decline over the past day and a larger pullback over the past week, month, and past three months. See our latest analysis for PG&E. That short term weakness adds to a 1 month share price return of an 8.1% decline and a year to date share price return of a 0.5% decline, while the 5 year total shareholder return of 54.5% shows earlier momentum that has cooled in recent...

Wondering whether Verra Mobility stock is starting to look appealing at its current price, especially after a tough run? This article focuses squarely on what that price might really imply about value. The stock last closed at US$14.63 and has returned 0.5% over 30 days, yet year to date it is down 34.5% and the 1 year return is a 39.7% decline, which can change how investors think about both risk and opportunity. Recent coverage has focused on how the stock's weaker 1 year and 3 year...

Serve Robotics (SERV) has posted FY 2025 results that highlight a small but growing top line alongside sizable losses, with Q4 revenue at about US$0.9 million and a quarterly net loss of roughly US$34.3 million, or EPS of US$0.46 loss, while trailing 12 month revenue sits at roughly US$2.7 million against a net loss of about US$101.4 million and EPS of US$1.63 loss. Over recent quarters the company has seen revenue move from around US$0.18 million in Q4 FY 2024 to US$0.88 million in Q4 FY...

Akebia Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$53.54 million versus US$57.34 million a year earlier, with net loss of US$9.05 million replacing prior net income of US$6.11 million. A recent proposal to increase authorized capital stock to 525,000,000 shares, including 500,000,000 common shares, adds a potential dilution and financing angle to Akebia’s weaker quarterly performance. Next, we’ll examine how the shift to a quarterly loss alongside...